Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 108

1.

Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study.

McClung MR, Brown JP, Diez-Perez A, Resch H, Caminis J, Meisner P, Bolognese MA, Goemaere S, Bone HG, Zanchetta JR, Maddox J, Bray S, Grauer A.

J Bone Miner Res. 2018 Aug;33(8):1397-1406. doi: 10.1002/jbmr.3452. Epub 2018 May 22.

PMID:
29694685
2.

Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial.

Bilezikian JP, Hattersley G, Fitzpatrick LA, Harris AG, Shevroja E, Banks K, Leder BZ, Zanchetta JR, Hans D.

Osteoporos Int. 2018 Feb;29(2):323-328. doi: 10.1007/s00198-017-4304-9. Epub 2017 Nov 22.

3.

Improved Bone Microarchitecture in Patients With Celiac Disease After 3 Years on a Gluten-Free Diet.

Zanchetta MB, Costa AF, Longobardi V, Mazure R, Silveira F, Temprano MP, Vázquez H, Bogado C, Niveloni SI, Smecuol E, Moreno ML, González A, Mauriño E, Zanchetta JR, Bai JC.

Clin Gastroenterol Hepatol. 2018 May;16(5):774-775. doi: 10.1016/j.cgh.2017.09.054. Epub 2017 Oct 6. No abstract available.

PMID:
28993260
4.

Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study.

Zanchetta MB, Boailchuk J, Massari F, Silveira F, Bogado C, Zanchetta JR.

Osteoporos Int. 2018 Jan;29(1):41-47. doi: 10.1007/s00198-017-4242-6. Epub 2017 Oct 3.

PMID:
28975362
5.

Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.

McClung MR, Lippuner K, Brandi ML, Zanchetta JR, Bone HG, Chapurlat R, Hans D, Wang A, Zapalowski C, Libanati C.

Osteoporos Int. 2017 Oct;28(10):2967-2973. doi: 10.1007/s00198-017-4140-y. Epub 2017 Jul 26.

PMID:
28748386
6.

Retreatment with teriparatide: our experience in three patients with severe secondary osteoporosis.

Mana DL, Zanchetta MB, Zanchetta JR.

Osteoporos Int. 2017 Apr;28(4):1491-1494. doi: 10.1007/s00198-016-3869-z. Epub 2016 Dec 14.

PMID:
27966106
7.

Denosumab Reduces Cortical Porosity of the Proximal Femoral Shaft in Postmenopausal Women With Osteoporosis.

Zebaze R, Libanati C, McClung MR, Zanchetta JR, Kendler DL, Høiseth A, Wang A, Ghasem-Zadeh A, Seeman E.

J Bone Miner Res. 2016 Oct;31(10):1827-1834. doi: 10.1002/jbmr.2855. Epub 2016 May 19.

8.

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.

Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C; ACTIVE Study Investigators.

JAMA. 2016 Aug 16;316(7):722-33. doi: 10.1001/jama.2016.11136. Erratum in: JAMA. 2017 Jan 24;317(4):442.

PMID:
27533157
9.

Impaired Bone Microarchitecture Improves After One Year On Gluten-Free Diet: A Prospective Longitudinal HRpQCT Study in Women With Celiac Disease.

Zanchetta MB, Longobardi V, Costa F, Longarini G, Mazure RM, Moreno ML, Vázquez H, Silveira F, Niveloni S, Smecuol E, de la Paz Temprano M, Massari F, Sugai E, González A, Mauriño EC, Bogado C, Zanchetta JR, Bai JC.

J Bone Miner Res. 2017 Jan;32(1):135-142. doi: 10.1002/jbmr.2922. Epub 2016 Oct 3.

10.

Bone microarchitecture in Rett syndrome and treatment with teriparatide: a case report.

Zanchetta MB, Scioscia MF, Zanchetta JR.

Osteoporos Int. 2016 Sep;27(9):2873-2877. doi: 10.1007/s00198-016-3586-7. Epub 2016 Apr 11.

PMID:
27068223
11.

Significant bone microarchitecture impairment in premenopausal women with active celiac disease.

Zanchetta MB, Costa F, Longobardi V, Longarini G, Mazure RM, Moreno ML, Vázquez H, Silveira F, Niveloni S, Smecuol E, Temprano Mde L, Hwang HJ, González A, Mauriño EC, Bogado C, Zanchetta JR, Bai JC.

Bone. 2015 Jul;76:149-57. doi: 10.1016/j.bone.2015.03.005. Epub 2015 Mar 14.

PMID:
25779933
12.

Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.

Leder BZ, O'Dea LS, Zanchetta JR, Kumar P, Banks K, McKay K, Lyttle CR, Hattersley G.

J Clin Endocrinol Metab. 2015 Feb;100(2):697-706. doi: 10.1210/jc.2014-3718. Epub 2014 Nov 13.

PMID:
25393645
13.

Romosozumab in postmenopausal women with low bone mineral density.

McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG.

N Engl J Med. 2014 Jan 30;370(5):412-20. doi: 10.1056/NEJMoa1305224. Epub 2014 Jan 1.

14.

Differing effects of denosumab and alendronate on cortical and trabecular bone.

Zebaze RM, Libanati C, Austin M, Ghasem-Zadeh A, Hanley DA, Zanchetta JR, Thomas T, Boutroy S, Bogado CE, Bilezikian JP, Seeman E.

Bone. 2014 Feb;59:173-9. doi: 10.1016/j.bone.2013.11.016. Epub 2013 Nov 22.

15.

Assessment of bone microarchitecture in postmenopausal women on long-term bisphosphonate therapy with atypical fractures of the femur.

Zanchetta MB, Diehl M, Buttazzoni M, Galich A, Silveira F, Bogado CE, Zanchetta JR.

J Bone Miner Res. 2014 Apr;29(4):999-1004. doi: 10.1002/jbmr.2107.

16.

Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab.

Genant HK, Libanati C, Engelke K, Zanchetta JR, Høiseth A, Yuen CK, Stonkus S, Bolognese MA, Franek E, Fuerst T, Radcliffe HS, McClung MR.

Bone. 2013 Oct;56(2):482-8. doi: 10.1016/j.bone.2013.07.011. Epub 2013 Jul 17.

17.

Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab.

Keaveny TM, McClung MR, Genant HK, Zanchetta JR, Kendler D, Brown JP, Goemaere S, Recknor C, Brandi ML, Eastell R, Kopperdahl DL, Engelke K, Fuerst T, Radcliffe HS, Libanati C.

J Bone Miner Res. 2014 Jan;29(1):158-65. doi: 10.1002/jbmr.2024.

18.

A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year data.

McClung MR, Benhamou CL, Man Z, Tlustochowicz W, Zanchetta JR, Eusebio R, Balske AM, Matzkin E, Olszynski WP, Recker R, Delmas PD.

Calcif Tissue Int. 2013 Jan;92(1):59-67. doi: 10.1007/s00223-012-9668-4. Epub 2012 Nov 13.

19.

Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.

McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL, Man Z, Eusebio RA, Beary JF, Burgio DE, Matzkin E, Boonen S, Delmas P.

Osteoporos Int. 2013 Jan;24(1):293-9. doi: 10.1007/s00198-012-2056-0. Epub 2012 Jun 30.

20.

Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis.

McClung MR, Zanchetta JR, Høiseth A, Kendler DL, Yuen CK, Brown JP, Stonkus S, Goemaere S, Recknor C, Woodson GC, Bolognese MA, Franek E, Brandi ML, Wang A, Libanati C.

J Clin Densitom. 2013 Apr-Jun;16(2):250-6. doi: 10.1016/j.jocd.2012.02.014. Epub 2012 May 8.

PMID:
22572531

Supplemental Content

Loading ...
Support Center